KQ 791

Drug Profile

KQ 791

Alternative Names: KQ791

Latest Information Update: 02 Mar 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Kaneq Bioscience
  • Class Antihyperglycaemics; Insulin sensitisers
  • Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Insulin resistance; Type 2 diabetes mellitus

Most Recent Events

  • 01 Feb 2016 Kaneq Bioscience completes a phase I trial in Type-2 diabetes in USA (NCT02445911)
  • 01 Jul 2015 Kaneq Bioscience completes a phase I trial in Insulin resistance (In volunteers) in Canada (NCT02370043)
  • 01 Jun 2015 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO) (NCT02445911)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top